1
|
Jiang Y, Dincer Yilmaz NE, Barker KP, Baek J, Xia Y, Zheng X. Enhancing Mechanical and Combustion Performance of Boron/Polymer Composites via Boron Particle Functionalization. ACS APPLIED MATERIALS & INTERFACES 2021; 13:28908-28915. [PMID: 34110148 DOI: 10.1021/acsami.1c06727] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
High-speed air-breathing propulsion systems, such as solid fuel ramjets (SFRJ), are important for space exploration and national security. The development of SFRJ requires high-performance solid fuels with excellent mechanical and combustion properties. One of the current solid fuel candidates is composed of high-energy particles (e.g., boron (B)) and polymeric binder (e.g., hydroxyl-terminated polybutadiene (HTPB)). However, the opposite polarities of the boron surface and HTPB lead to poor B particle dispersion and distribution within HTPB. Herein, we demonstrate that the surface functionalization of B particles with nonpolar oleoyl chloride greatly improves the dispersion and distribution of B particles within HTPB. The improved particle dispersion is quantitatively visualized through X-ray computed tomography imaging, and the particle/matrix interaction is evaluated by dynamic mechanical analysis. The surface-functionalized B particles can be uniformly dispersed up to 40 wt % in HTPB, the highest mass loading reported to date. The surface-functionalized B (40 wt %)/HTPB composite exhibits a 63.3% higher Young's modulus, 87.5% higher tensile strength, 16.2% higher toughness, and 16.8% higher heat of combustion than pristine B (40 wt %)/HTPB. The surface functionalization of B particles provides an effective strategy for improving the efficacy and safety of B/HTPB solid fuels for future high-speed air-breathing vehicles.
Collapse
Affiliation(s)
- Yue Jiang
- Department of Mechanical Engineering, Stanford University, Stanford, California 94305, United States
| | - Nil Ezgi Dincer Yilmaz
- Department of Mechanical Engineering, Stanford University, Stanford, California 94305, United States
| | - Kayla P Barker
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Jihyun Baek
- Department of Mechanical Engineering, Stanford University, Stanford, California 94305, United States
| | - Yan Xia
- Department of Chemistry, Stanford University, Stanford, California 94305, United States
| | - Xiaolin Zheng
- Department of Mechanical Engineering, Stanford University, Stanford, California 94305, United States
| |
Collapse
|
4
|
Hassan AHE, Park HR, Yoon YM, Kim HI, Yoo SY, Lee KW, Lee YS. Antiproliferative 3-deoxysphingomyelin analogs: Design, synthesis, biological evaluation and molecular docking of pyrrolidine-based 3-deoxysphingomyelin analogs as anticancer agents. Bioorg Chem 2018; 84:444-455. [PMID: 30576908 DOI: 10.1016/j.bioorg.2018.11.040] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 11/21/2018] [Accepted: 11/24/2018] [Indexed: 12/13/2022]
Abstract
Sphingomyelins and glycerophospholipids are structurally related phospholipids. Nevertheless, glycerophospholipids analogs are known as antitumor agents while sphingomyelin analogs were reported as cytoprotective agents. Herein, we have addressed the development of 3-deoxysphingomyelin analogs as cytotoxic agents possessing modified sphingobases. Thus, pyrrolidine-based 3-deoxysphingomyelin analogs were synthesized and evaluated against a panel of cell lines representing four major types of cancers. Compounds 3d, 4d and 6d elicited better GI50 values than the FDA approved drug miltefosine. Investigation of their impact on Akt phosphorylation as a possible mechanism for the antiproliferative activity of this class of compounds revealed that these compounds might elicit a concentration-dependent mechanism via inhibition of Akt phosphorylation at the lower concentration. Molecular docking predicted their binding modes to Akt to involve polar head binding to the Pleckstrin homology domain and hydrophobic tail extension into a hydrophobic pocket connecting the Pleckstrin homology domain and the kinase domain. As a whole, the described work suggests compounds 3d, 4d and 6d as promising pyrrolidine-based 3-deoxysphingomyelin analogs for development of novel cancer therapies.
Collapse
Affiliation(s)
- Ahmed H E Hassan
- Medicinal Chemistry Laboratory, Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea; Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
| | - Hye Rim Park
- Department of Life and Nanopharmaceutical Science, Kyung Hee University, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Yoon Mi Yoon
- Department of Life and Nanopharmaceutical Science, Kyung Hee University, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Hye In Kim
- Department of Life and Nanopharmaceutical Science, Kyung Hee University, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Sung Yeun Yoo
- Department of Life and Nanopharmaceutical Science, Kyung Hee University, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Kun Won Lee
- Department of Life and Nanopharmaceutical Science, Kyung Hee University, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Yong Sup Lee
- Medicinal Chemistry Laboratory, Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea; Department of Life and Nanopharmaceutical Science, Kyung Hee University, Kyung Hee University, Seoul 02447, Republic of Korea.
| |
Collapse
|
5
|
Gómez de Cedrón M, Vargas T, Madrona A, Jiménez A, Pérez-Pérez MJ, Quintela JC, Reglero G, San-Félix A, Ramírez de Molina A. Novel Polyphenols That Inhibit Colon Cancer Cell Growth Affecting Cancer Cell Metabolism. J Pharmacol Exp Ther 2018; 366:377-389. [PMID: 29871992 DOI: 10.1124/jpet.118.248278] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 06/01/2018] [Indexed: 12/30/2022] Open
Abstract
New series of polyphenols with a hydrophilic galloyl-based head and a hydrophobic N-acyl tail, linked through a serinol moiety, have been synthesized and tested against colon cancer cell growth. Our structure activity relationship studies revealed that galloyl moieties are essential for growth inhibition. Moreover, the length of the N-acyl chain is crucial for the activity. Introduction of a (Z) double bond in the acyl chain increased the anticancer properties. Our findings demonstrate that 16, the most potent compound within this series, has inhibitory effects on colon cancer cell growth and metabolism (glycolysis and mitochondrial respiration) at the same time that it activates 5'AMP-activated kinase (AMPK) and induces apoptotic cell death. Based on these results, we propose that 16 might reprogram colon cancer cell metabolism through AMPK activation. This might lead to alterations on cancer cell bioenergy compromising cancer cell viability. Importantly, these antiproliferative and proapoptotic effects are selective for cancer cells. Accordingly, these results indicate that 16, with an unsaturated C18 chain, might be a useful prototype for the development of novel colon cancer cell growth inhibitors affecting cell metabolism.
Collapse
Affiliation(s)
- Marta Gómez de Cedrón
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - Teodoro Vargas
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - Andrés Madrona
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - Aranza Jiménez
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - María-Jesús Pérez-Pérez
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - José-Carlos Quintela
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - Guillermo Reglero
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - Ana San-Félix
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| | - Ana Ramírez de Molina
- Molecular Oncology and Nutritional Genomics of Cancer, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain (M.G.d.C., T.V., G.R., A.R.d.M.); Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, Madrid, Spain (A.M., A.J., M.-J.P.-P., A.S.-F.); and Natac Biotech S.L., Parque Científico de Madrid, Campus de Cantoblanco, Madrid, Spain (J.-C.Q.)
| |
Collapse
|